Open | $150.680 |
Close | $147.410 |
Volume / Avg. | 460.718K / 852.888K |
Day Range | 147.180 - 151.000 |
52 Wk Range | 143.520 - 218.880 |
Market Cap | $18.566B |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 35 |
Short Interest | 4.18% |
Days to Cover | 3.16 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Alnylam Pharmaceuticals (NASDAQ: ALNY) through any online brokerage.
Other companies in Alnylam Pharmaceuticals’s space includes: Legend Biotech (NASDAQ:LEGN), Sarepta Therapeutics (NASDAQ:SRPT), Exact Sciences (NASDAQ:EXAS), Neurocrine Biosciences (NASDAQ:NBIX) and Karuna Therapeutics (NASDAQ:KRTX).
The latest price target for Alnylam Pharmaceuticals (NASDAQ: ALNY) was reported by HC Wainwright & Co. on Tuesday, March 5, 2024. The analyst firm set a price target for 395.00 expecting ALNY to rise to within 12 months (a possible 167.96% upside). 65 analyst firms have reported ratings in the last year.
The stock price for Alnylam Pharmaceuticals (NASDAQ: ALNY) is $147.41 last updated March 18, 2024 at 4:52 PM EDT.
There are no upcoming dividends for Alnylam Pharmaceuticals.
Alnylam Pharmaceuticals’s Q1 earnings are confirmed for Thursday, May 2, 2024.
There is no upcoming split for Alnylam Pharmaceuticals.
Alnylam Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.